JNJ-0819

N/A

Report date: 2026/03/19 16:57:31

Base Information

Drug NameJNJ-0819

Drug Alias NameJNJ-0819

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsHeme oxygenase inhibitors

TargetsHeme oxygenaseT cell surface glycoprotein CD3

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesJanssen Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesJanssen Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A